{"title":"Discontinuation of antipsychotics initiated in hospital improves older-adult outcomes","authors":"","doi":"10.1002/pu.31351","DOIUrl":"https://doi.org/10.1002/pu.31351","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144773580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Paternal exposure to valproate not linked to child neurodevelopmental disorders","authors":"","doi":"10.1002/pu.31353","DOIUrl":"https://doi.org/10.1002/pu.31353","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144773582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Oveporexton improves sleep outcomes in patients with narcolepsy","authors":"","doi":"10.1002/pu.31348","DOIUrl":"https://doi.org/10.1002/pu.31348","url":null,"abstract":"<p>The orexin receptor 2-selective agonist oveporexton improved sleep- and wakefulness-related measures in a dose-dependent fashion relative to placebo in adults with narcolepsy type 1, a Phase 2 study has found. Most adverse events associated with oveporexton were mild to moderate, with no reports of suicidality.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144773908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clozapine-associated pneumonia","authors":"Y. W. Francis Lam Pharm.D., FCCP","doi":"10.1002/pu.31346","DOIUrl":"https://doi.org/10.1002/pu.31346","url":null,"abstract":"<p>Despite clozapine's recognized efficacy for patients with treatment-resistant schizophrenia, most clinicians are aware that it can cause such serious adverse effects as agranulocytosis, seizures, myocarditis, obstipation, and orthostatic hypotension. Less well known are clinical reports and research suggesting an increased risk of pneumonia (Cepaityte et al., 2021). Other than dosage reduction, there has been little guidance on prevention of clozapine-associated pneumonia, or whether clozapine can be reinstated after its resolution.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 9","pages":"2-6"},"PeriodicalIF":0.0,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144773911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Esketamine's effects in combination with SSRI vs. SNRI show differences","authors":"","doi":"10.1002/pu.31332","DOIUrl":"https://doi.org/10.1002/pu.31332","url":null,"abstract":"<p>A retrospective cohort study has found that while esketamine is effective in combination with an antidepressant in patients with treatment-resistant depression, effects differ based on antidepressant class. Patients receiving esketamine with a serotonin-norepinephrine reuptake inhibitor (SNRI) showed improvement on more measures in comparison with the combination of esketamine and a selective serotonin reuptake inhibitor (SSRI). Study results were published online April 2, 2025, in <i>JAMA Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 8","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"GLP-1s, SGLT2s associated with lower risk of Alzheimer's disease","authors":"","doi":"10.1002/pu.31339","DOIUrl":"https://doi.org/10.1002/pu.31339","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Herpes zoster vaccine has protective effect against dementia","authors":"","doi":"10.1002/pu.31338","DOIUrl":"https://doi.org/10.1002/pu.31338","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A second Phase 3 trial affirms efficacy of cytisinicline for smoking cessation","authors":"","doi":"10.1002/pu.31334","DOIUrl":"https://doi.org/10.1002/pu.31334","url":null,"abstract":"<p>Smokers receiving the plant-based alkaloid cytisinicline with behavioral support showed significantly higher smoking abstinence rates compared with those receiving placebo with behavioral support, a Phase 3 replication trial has found. The incidence of adverse events was similar between the cytisinicline and placebo groups.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 8","pages":"3-4"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Review suggests need to monitor blood pressure in youths receiving ADHD medications","authors":"","doi":"10.1002/pu.31336","DOIUrl":"https://doi.org/10.1002/pu.31336","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}